Prescribing advice

Glucagon-like peptide-1 (GLP-1) analogues act as GLP-1 receptor agonists.

An updated Medicine Supply Notification (MSN) was issued on 18 March 2024 and the details can be viewed in the following Supply Tool post:

• Shortage of GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide, exenatide)

This information supersedes the updated National Patient Safety Alert (NatPSA) on the shortage of GLP-1 receptor agonists on 3 January 2024.

The original NatPSA issued on 18 July 2023 is still available to access.

Prescribing advice is available from the following key resources listed in the NatPSA:

• Type 2 diabetes in adults: management (NICE guideline [NG28])
• Joint PCDS and ABCD guidance: GLP-1 receptor agonist national shortage
• Obesity: identification, assessment and management (NICE clinical guideline [CG189])

Dulaglutide

Limited availability

The following dulaglutide products will be in limited supply and are unable to support uplift in demand from other GLP-1 receptor agonists:

• Trulicity 0.75 mg solution for injection in pre-filled pen
• Trulicity 1.5 mg solution for injection in pre-filled pen
• Trulicity 3 mg solution for injection in pre-filled pen
• Trulicity 4.5 mg solution for injection in pre-filled pen

Affected

The following active supply issues exist:

• Shortage of Dulaglutide (Trulicity) 0.75mg, 1.5mg, 3mg and 4.5mg solution for injection devices

Exenatide

Available

The following exenatide products are available but are unable to support uplift in demand from other GLP-1 receptor agonists:

• Byetta 5micrograms/0.02mL solution for injection 1.2mL pre-filled pens
• Bydureon 2mg/0.85mL prolonged-release suspension for injection 1.2mL pre-filled pens

Affected

The following active supply issues exist:

• Archived: Discontinuation of Exenatide (Byetta) 5microgram/0.02ml and 10microgram/0.04ml solution for injection

Liraglutide

Limited availability

The following injectable liraglutide products will be in limited supply and are unable to support uplift in demand from other GLP-1 receptor agonists:

• Victoza 6mg/mL solution for injection in prefilled pen
• Saxenda 6mg/mL solution for injection in prefilled pen

Affected

The following active supply issues exist:

• Shortage of Liraglutide (Victoza) 6mg/ml solution for injection
• Shortage of Liraglutide (Saxenda) 6mg/ml solution for injection 3ml pre-filled disposable devices

Semaglutide injection

Limited availability

The following injectable semaglutide products will be in limited supply and are unable to support uplift in demand from other GLP-1 receptor agonists:

• Ozempic 0.25mg solution for injection in pre-filled pen
• Ozempic 1mg solution for injection in pre-filled pen

Available

Wegovy (semaglutide) is now available in the following presentations by Novo Nordisk:

• Wegovy 0.25mg FlexTouch solution for injection in pre-filled pen
• Wegovy 0.5mg FlexTouch solution for injection in pre-filled pen
• Wegovy 1mg FlexTouch solution for injection in pre-filled pen
• Wegovy 1.7mg FlexTouch solution for injection in pre-filled pen
• Wegovy 2.4mg FlexTouch solution for injection in pre-filled pen

Accessing Wegovy for weight loss: Everything you need to know contains further information regarding access on the NHS.

Affected

The following active supply issues exist:

• Ozempic 0.5mg solution for injection in pre-filled pen

Shortage of Semaglutide (Ozempic) solution for injections contains further information.

Semaglutide tablets

Available

Rybelsus tablets are now available in sufficient quantities to support initiation of GLP-1 receptor agonist treatment in people with type 2 diabetes (T2DM):

• Rybelsus 3mg tablets
• Rybelsus 7mg tablets
• Rybelsus 14mg tablets

Further advice

Update history